Angidin MR Tablet (Modified Release)
Angidin MR is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart. This leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.
Long-term treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction).
Angidin MR is also used to associated treatment for these conditions: Angina Pectoris, Chronic Stable Angina Pectoris, Dizziness, Tinnitus, Decreased visual acuity caused by Vascular Disorders
|Trade Name||Angidin MR|
|Other Names||Trimetazidina, Trimetazidine|
|Type||Tablet (Modified Release)|
Trimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.
|Therapeutic Class||Other Anti-anginal & Anti-ischaemic drugs|
|Manufacturer||Leon Pharmaceuticals Ltd|
|Last Updated:||June 23, 2021 at 11:26 am|
Table Of contents
Angidin MR dosage
One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.
One 35 mg modified release tablet twice daily at mealtimes in the morning and evening.
Angidin MR is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.
No drug interactions have so far been reported. In particular, no interactions of Angidin MR with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.
- Take with food. Take during a meal.
- Take with plain water. Take with a glass of water.
Volume of Distribution
The volume of distribution of trimetazidine is 4.8 L/kg.
In young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.
Angidin MR clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.
Pregnancy & Breastfeeding use
Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Nursing Mothers: There is no information on the secretion of Angidin MR into breast milk. However, breast feeding should be discontinued if the use of Angidin MR is considered essential.
Hypersensitivity to Angidin MR Dihydrochloride.
Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.